Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
J Orthop Res. 2013 Jul;31(7):999-1006. doi: 10.1002/jor.22324. Epub 2013 Feb 19.
A case-control study was conducted to estimate the association of cartilage oligomeric matrix protein (COMP) with knee osteoarthritis (OA) and to examine the potential utility of COMP as a diagnostic and prognostic biomarker in early knee OA. The COMP levels were estimated in the blood sera of 150 subjects belonging to study group (n = 100) and control one (n = 50). Patients with confirmed clinical isolated knee OA diagnosed through American College of Rheumatology criteria were included and were without any other cause of knee pain. ELISA was used to determine the levels of COMP, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). The median (range) serum COMP levels were observed to be 1117.21 ng/ml (125.03-4209.75 ng/ml) in OA patients and 338.62 ng/ml (118-589 ng/ml) in control subjects with p < 0.001. The COMP levels of study group were negatively correlated (correlation factor -0.88) with disease duration and positively correlated with age, BMI, pain score and IL-1β with correlation factors 0.86, 0.63, 0.76, and 0.79, respectively with p < 0.001. Gender differentiation was found in study group with 52% higher COMP level in males as compared to that of females. There was no significant correlation of COMP levels with radiological grading, erythrocyte sedimentation rate (ESR), hemoglobin (Hb), and TNF-α. The serum COMP levels may be used as a diagnostic OA marker along with prognostic value in determining the patients at risk of rapidly progressing this debilitating joint disease. The serum COMP level remains significantly high in first 3 years of disease duration.
一项病例对照研究旨在评估软骨寡聚基质蛋白（COMP）与膝骨关节炎（OA）的相关性，并研究 COMP 作为早期膝 OA 的诊断和预后生物标志物的潜在效用。在属于研究组（n=100）和对照组（n=50）的 150 名受试者的血清中估计了 COMP 水平。通过美国风湿病学会标准确诊为临床孤立性膝 OA 的患者被纳入研究，且无任何其他膝关节疼痛的原因。ELISA 用于测定 COMP、白细胞介素 1β（IL-1β）和肿瘤坏死因子-α（TNF-α）的水平。OA 患者的血清 COMP 水平中位数（范围）为 1117.21ng/ml（125.03-4209.75ng/ml），对照组为 338.62ng/ml（118-589ng/ml），p<0.001。研究组的 COMP 水平与疾病持续时间呈负相关（相关系数-0.88），与年龄、BMI、疼痛评分和 IL-1β呈正相关，相关系数分别为 0.86、0.63、0.76 和 0.79，p<0.001。在研究组中发现了性别差异，男性的 COMP 水平比女性高 52%。COMP 水平与放射学分级、红细胞沉降率（ESR）、血红蛋白（Hb）和 TNF-α无显著相关性。血清 COMP 水平可作为诊断 OA 的标志物，并具有预后价值，可用于确定处于快速进展这种致残性关节疾病风险的患者。在疾病持续时间的前 3 年内，血清 COMP 水平仍然显著升高。
